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Daunorubicin (DNR) is an anthracycline antibiotic introduced in the late 1960s for the treatment of leukaemia. It has been one of the major agents used in the treatment of acute leukaemia. A factor limiting the effectiveness of this drug is the development of resistance by the leukaemia. In the last 10 years there has been the discovery of multidrug resistance (MDR) (Pastan & Gottesman, 1987; Bradley et al., 1988; Kartner & Ling, 1989) , in which the development of resistance to one chemotherapeutic agent leads to the resistance to a number of other chemotherapeutic agents to which the cultured tumour cells have not been exposed. One of the agents involved in MDR is DNR. In vitro, MDR is associated with the presence of a protein called P-glycoprotein (Pgp) , and it has been hypothesised that intracellular cytotoxic agents are removed from the cell via Pgp, thus decreasing the intracellular concentration and the effectiveness of these drugs. Although the relationship between cellular drug concentrations and Pgp has been well established in cell lines (Kartner et al., 1983; Fojo et al., 1985) , this relationship has not been well documented in patients undergoing chemotherapy. We (Ma et al., 1987) and others, for example Campos et al. (1992) , have shown that the Pgp phenotype is present in patients with leukaemia. Previous studies have examined the pharmacokinetics of DNR in patients (Alberts et al., 1971; Speth et al., 1987; Kokenberg et al., 1988; Paul et al., 1989 ), but few have investigated the cellular levels of DNR and its major cytotoxic metabolite daunorubicinol (DOL) and treatment response. One issue is whether the resistance to DNR is due simply to altered plasma kinetics resulting in inadequate cellular DNR concentrations or to a mechanism involving Pgp. In this study we examined the plasma and cellular pharmacokinetics of DNR Table I .
Patients received DNR (David Bull Laboratories, Victoria, Australia) infused over a 15 min period (Table I) as part of their induction chemotherapy. For AML patients the chemotherapy protocol consisted of Ara-C 100 mg m-2 day-' with or without etoposide 75 mg m-2 day-' for 7 days and DNR 50 mg m-2 for 3 days (in two patients the doses were reduced because of concern about accumulated cardiotoxicity). For ALL patients the Hoelzer protocol (Hoelzer et al., 1984) was used, which consisted of daily prednisolone with weekly injections of DNR 25 mg m-2 and vincristine over the first 4 weeks of induction.
Response was determined according to standard criteria as follows: a complete remission (CR) was defined as a reduction of blast cells below 5% and a return to normal haematopoiesis within 4 weeks after the commencement of chemotherapy; a partial response (PR) was defined as some reduction of blasts in the original population but without adequate normal haemopoietic recovery; no response was recorded when there was no alteration or an increase in the blasts. For analysis, patients with a partial response were grouped with those patients that had no response and are termed non-responders (NRs).
Collection of blood and sample preparations Blood samples were collected through a central venous catheter, in glass tubes containing ACDA (acid citrate dextrose A). A 10 ml sample of blood was collected and immediately placed on ice. Samples were taken before DNR infusion then at 15 min, 30min, 1 h, 1.5 h, 2 h, 4h, 6 h, 8 h, 10 h, 12 h and 24 h post infusion and then daily for 7 days. Blood samples were centrifuged at 500 g for 5 min and the plasma removed and stored at -80'C. The red cells were then removed by the addition of hypotonic lysis buffer (155 mM ammonium chloride, 10 mM potassium bicarbonate, 100 mM EDTA). The remaining white cells were immediately washed twice with cold phosphate-buffered saline (PBS) and resuspended in 1.3 ml of PBS. A small fraction was then taken for a white cell count and the remainder stored at -80'C. Only 14 of the patients had cellular samples stored, and the blast cell count in these samples had a median of 57% (Table I ). C) Macmifan Press Ltd., 1994 Br. J. Cancer (1994), 70, 324-329 
Analysis of daunorubicin and daunorubicinol
To 1 ml of plasma was added 50 ll of potassium hydroxide and 50;lI of adriamycin (ADR) (1 tLgml-') as an internal standard. The plasma was extracted with 10 ml of dichloromethane-isopropanol (9:1) by vortexing for 1 min. The samples were then centrifuged at 1,600 g for 5 min and the aqueous phase was removed. The organic phase was transferred to a clean glass tube and evaporated to dryness under reduced pressure. The dried extract was reconstituted in 150 jul of mobile phase (see below) and 50 pl injected onto the high-performance liquid chromatographic (HPLC) system (see below). The plasma calibration curve ranged from 5 to 120 ng ml-'. The intra-assay and inter-assay coefficients of variation for DNR at 25 ng ml-' were 13% and 14%, and at 100 ng ml-' were 6% and 14% respectively. The limit of detection was 5 ng ml-' for both DNR and DOL. Intracellular DNR and DOL were analysed by taking a known number of leukaemic cells (0.5-30 x 106 cells) in 1 ml of PBS. To this was added 100 id of 3 M hydrochloric acid in ethanol and the internal standard ADR (50 ng as for plasma). The cells were subjected to sonication for 5 min and extracted as described above. Standard curves were prepared using cell concentrations of untreated leukaemic cells similar to those being assayed. The cellular calibration curve ranged from 5 to 200 ng ml-The inter-assay coefficient of variation was 12%, and the intra-assay coefficient of variation at 25ngml-' was 3.1%, and at 150 ngml-' was 3.7%.
The analyses were performed using a reverse phase C,8 column (Waters Novapak 3.9 x 150 mm, 4 jAm). (Table I ).
Calculation ofpharmacokinetic parameters
The area under the curve (AUC) was calculated using the linear trapezoidal rule. To compare patients receiving different DNR doses, the AUCs were divided by the dose of DNR received. Standard equations were used to calculate the plasma half-life and clearance (Rowland & Tozer, 1989) .
Statistics
The Wilcoxon signed-rank test was used to compare differences between DNR and DOL AUCs. The X test was used to compare the relationship between Pgp and patient response, and the Mann-Whitney U-test was used for comparing differences between responding and non-responding patients. P<0.05 was considered significant.
Resuts
This study included 27 patients (Table I) , of whom 12 achieved complete remission, five had a partial response and six did not respond to chemotherapy. Four patients could not be evaluated because they died before a haematological response could be determined. The pharmacokinetic parameters for all patients are given in Table II . There is an inter-individual variation in both DNR and DOL AUC in the patients studied. The average plasma concentration-time curve for DNR and DOL for patients receiving a 50 mg m-2 dose of DNR is shown in Figure la . Figure la shows that the plasma DOL AUC-24h levels were significantly higher than plasma DNR for patients receiving a 50 mg m-2 dose of (Table H) . There was also no significant difference in the DNR plasma half-life (P>0.4) or clarnce (P>0.4) between patients that responded compared with those that did not (Table II) . The cellular concentration-time curve of patients receiving a S0mgm-2 dose of DNR is shown in Figure lb , with the cellular pharmacokinetic parameters given in Table H . The cellular AUC for DNR was significantly higher in all patients compared with the metabolite DOL (P<0.001). There was a significant difference in cellular DNR AUC (P < 0.03) between CR (232 ± 225 ng 106 cells, n = 5) patients and the NR (62 ± 24 ng 10-6 cells, n = 3) patients that received a 50 mg m-2 dose (Figure 2) . A similar difference in AUC (P<0.1) was also seen for DOL in these patients (Table I) .
Of the patients receiving a 25 mg m-2 dose of DNR, only 2/9 failed to respond to treatment, and data for cellular DNR and DOL AUC were available on only one of the nonresponders. Thus (Figure 3) . A similar difference was also seen for DOL (P<0.02) (Figure 3 (Felsted & Bachur, 1982 to recruit more patients to extend this study owing to the change in the clinical practice of the treatment of acute leukaemia. DNR having been replaced by newer anthracycline analogues (idarubicin) and anthracenes (mitoxantrone). To our knowledge. this is the first report investigating the relationship between Pgp and intracellular levels of DNR in patients. The cellular concentrations of DNR and DOL tended to be lower in those patients who were Pgp positive than in those who were not (Table III) (1991) found the complete remission rate to be 89% in mdrl RNA-negative patients and 53% in mdrl-positive patients. In contrast to the above findings, Holmes et al. (1989) established that the overexpression of the Pgp gene was not an important mechanism in previously untreated AML. In that study elevated levels of mdrl were seen in two out of eight patients with untreated AML, five out of eight with refractory AML and four out of five patients with secondary AML. Rothenberg et al. (1989) observed that eight out of nine patients with ALL at presentation had low levels of mdrl mRNA. In five patients at primary relapse, none had evidence of mdrl overexpression and 3 out of 15 patients with multiple relapses had elevated mdrl expression. They concluded that Pgp might play a role in some cases of drug resistance and that other mechanisms of resistance must exist. We have found no significant relationship between Pgp and patient response. Of the patients in this study, 17 out of 21 were previously untreated. Twelve of these patients were Pgp negative. with nine achieving complete remission (75%), and five were Pgp positive (2 5 achieving CR. 40%). Of the four patients that were previously treated. two were Pgp positive and two were Pgp negative. None of these patients responded to treatment. Our findings are similar to those of Rothenberg et al. (1989) , who showed low levels of Pgp at induction but higher levels of Pgp in multiple relapse patients.
In conclusion, a correlation between the intracellular DNR and DOL concentrations and patient response was observed in this study. The relationship between Pgp and intracellular drug concentrations was also examined. Although there was no statistical correlation between Pgp 'and intracellular drug concentrations, there was a tendency for patients who were Pgp positive to have decreased intracellular concentrations of DNR and DOL. A higher proportion of previously treated patients were Pgp positive, but no correlation was found between Pgp and patient response. suggesting that mechanism(s) of drug resistance other than Pgp are important in clinical resistance to DNR.
